ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Unicycive Therapeutics, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on October 14, 2025 [1]. Group 1: Class Action Details - Investors who bought Unicycive securities between March 29, 2024, and June 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm or visiting their website [3][6]. - The lead plaintiff must file a motion with the court by October 14, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Unicycive made false or misleading statements regarding its ability to meet FDA manufacturing compliance requirements and the regulatory prospects of its New Drug Application for oxylanthanum carbunate [5]. - The claims suggest that these misrepresentations led to investor damages when the true information became public [5].